Andelyn Biosciences, a prominent contract development and manufacturing organization (CDMO), has been chosen by Genprex, Inc. to assist in scaling up manufacturing for its innovative diabetes gene therapy program. This therapy aims to deliver the Pdx1 and MafA genes directly to the pancreas using an adeno-associated virus (AAV) vector. Genprex is developing this program as a potential solution for both type 1 and type 2 diabetes.
Focus on Gene Therapy
Under the new agreement, Andelyn will facilitate the transition of Genprex’s AAV-based diabetes gene therapy candidate through critical stages such as process optimization, scale-up, and manufacturing that supports Investigational New Drug (IND) applications and clinical trials. The collaboration will leverage Andelyn’s Curator Cell and Gene Therapy Platform, along with its extensive experience in AAV process development and technology transfer, to ensure effective analytical development and cGMP manufacturing.
Key Manufacturing Activities
The manufacturing efforts will encompass a variety of activities, including process optimization, scale-up, analytical qualification, potency assay development, and drug product manufacturing, all performed in a facility compliant with current Good Manufacturing Practices (cGMP). This structured approach is crucial for establishing a reliable foundation for Genprex’s upcoming clinical trials.
Advancements in Type 1 Diabetes
For type 1 diabetes, Genprex’s gene therapy candidate is designed to convert pancreatic alpha cells into functional beta-like cells that can produce insulin. Preclinical studies conducted in mouse models have shown promising results, with reports of normal blood glucose levels being maintained over extended periods. Additionally, nonhuman primate models have demonstrated reduced insulin requirements, increased C-peptide levels, and improved overall glucose tolerance.
Targeting Type 2 Diabetes
In the case of type 2 diabetes, where autoimmunity is not a significant factor, Genprex is exploring whether its gene therapy can rejuvenate and replenish insulin-producing beta cells, which often become exhausted. The company has reported encouraging preclinical outcomes in both mouse and nonhuman primate models.
Collaborative Enthusiasm
Matt Niloff, Chief Commercial Officer at Andelyn, expressed enthusiasm about the partnership, highlighting the significance of transitioning from academic or research-grade manufacturing to a scalable cGMP process. This transition is a crucial step in the development of advanced therapies. Andelyn’s team is committed to providing the necessary technical, operational, and quality expertise to support Genprex’s objectives for upcoming preclinical and clinical milestones.
Strategic Importance
Ryan Confer, President and CEO of Genprex, acknowledged that selecting Andelyn represents a critical advancement in preparing their diabetes gene therapy program for IND-enabling studies and subsequent clinical evaluations. He emphasized that Andelyn’s expertise in AAV development and cGMP manufacturing will be instrumental in moving the program forward.
Andelyn’s Experience
Andelyn Biosciences boasts over 20 years of experience in the field of cell and gene therapy, focusing on the development, characterization, and production of viral vectors for gene therapy. The organization has produced cGMP materials for more than 500 clinical batches and has participated in 85 global clinical trials, showcasing its deep scientific expertise and commitment to advancing therapeutic solutions.
Genprex’s Vision
Genprex, Inc. is a clinical-stage gene therapy company dedicated to creating transformative therapies for patients battling cancer and diabetes. Their technologies aim to deliver disease-fighting genes that provide new treatment options for large patient populations facing limited alternatives.
In conclusion, the collaboration between Andelyn Biosciences and Genprex marks a significant milestone in the evolution of diabetes gene therapy. By combining their expertise, they are poised to make meaningful advancements in the treatment landscape for diabetes, offering hope to patients worldwide. This partnership exemplifies the ongoing innovation in gene therapy, emphasizing the potential to change lives through advanced medical solutions.
- Andelyn Biosciences chosen by Genprex for manufacturing support.
- Focus on AAV-based gene therapy for type 1 and type 2 diabetes.
- Key activities include process optimization and cGMP manufacturing.
- Preclinical results show promise in restoring insulin production.
- Partnership aims to advance diabetes treatment options.
Read more → www.pharmabiz.com
